Page last updated: 2024-12-05

ethoglucid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Ethoglucid: Alkylating antineoplastic agent used especially in bladder neoplasms. It is toxic to hair follicles, gastro-intestinal tract, and vasculature. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

imidazole mustard: inhibitor of purine nucleoside synthesis; minor descriptor (77-84); on-line & Index Medicus search NITROGEN MUSTARD COMPOUNDS (77-84); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16058
CHEMBL ID460287
CHEBI ID82542
SCHEMBL ID8442
MeSH IDM0007884
PubMed CID6433428
MeSH IDM0007884

Synonyms (67)

Synonym
etoglucid (inn)
D07256
1,3-epoxypropoxy)ethoxy]ethane
triethylene glycol,3-epoxypropyl) ether
oxirane,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bis-
etoglucid
nsc-80439
diglycidyltriethylene glycol
ayerst 62013
ici 32865
1954-28-5
ethoglucid
ethane,2-bis[2-(2,3-epoxypropoxy)ethoxy]-
nsc80439
wln: t3otj b1o2o2o2o1- bt3otj
triethylene glycol diglycidyl ether
epodyl
2,5,8,11-tetraoxa-1,12-dodecanediyl)bisoxirane
ici32865
1,16-diepoxy-4,7,10,13-tetraoxahexadecane
etoglucide
4,10,13-tetraoxahexadecane, 1,2:15,16-diepoxy-
triethylene glycol, bis(2,3-epoxypropyl) ether
brn 4311213
1,2-bis(2-(2,3-epoxypropoxy)ethoxy)ethane
etoglucide [inn-french]
ici-32865
etoglucido [inn-spanish]
ethane, 1,2-bis(2-(2,3-epoxypropoxy)ethoxy)-
1,2:15,16-diepoxy-4,7,10,13-tetraoxahexadecane
etoglucid [inn]
4,7,10,13-tetraoxahexadecane, 1,2:15,16-diepoxy-
etoglucidum [inn-latin]
oxirane, 2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bis-
2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bisoxirane
einecs 217-784-7
ethoglucide
2,2'-(2,5,8,11-tetraoxa-1,12-dodecane diyl)bisoxirane
nsc 80439
2-[2-[2-[2-(oxiran-2-ylmethoxy)ethoxy]ethoxy]ethoxymethyl]oxirane
CHEMBL460287
chebi:82542 ,
2-[2-[2-[2-(oxiran-2-yl-methoxy)-ethoxy]-ethoxy]-ethoxy-methyl]-oxirane
C19537
etoglucido
etoglucid [inn:ban]
etoglucidum
unii-4f9kua0t4d
4f9kua0t4d ,
5-17-03-00020 (beilstein handbook reference)
AKOS015905688
etoglucid [mart.]
etoglucid [who-dd]
etoglucid [mi]
SCHEMBL8442
Q548286
1,12-di(oxiran-2-yl)-2,5,8,11-tetraoxadodecane
DB13339
DTXSID80862800
2,2'-(2,5,8,11-tetraoxa-1,12-dodecanediyl)bisoxirane
etoglucide; ici 32865; nsc 80439; tde
4-methyl-5-acetylthiazole
5-(3,3-bis(2-chlorethyl)-1-triazeno)-imidazole-4-carboxamide
brn 0808683
imidazole mustard
4-[(e)-bis(2-chloroethyl)aminodiazenyl]-4h-imidazole-5-carboxamide
unii-oy338x4m2p

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409955Inhibition of mouse liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (81)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (80.25)18.7374
1990's11 (13.58)18.2507
2000's4 (4.94)29.6817
2010's1 (1.23)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (18.99%)5.53%
Trials1 (20.00%)5.53%
Reviews12 (15.19%)6.00%
Reviews0 (0.00%)6.00%
Case Studies4 (5.06%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other48 (60.76%)84.16%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]